Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
  • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton

Definitions

• the invention relates to compositions and methods for the treatment of cancer.
• Extracellular signals received attransmembrane receptors are relayed into the cells by the signal transduction pathways (Pelech et al., Science 257:1335 (1992)) which have been implicated in a wide array of physiological processes such as induction of cell proliferation, differentiation orapoptosis (Davis etal., J. Biol. Chem. 268:14553 (1993)).
• the Mitogen Activated Protein Kinase (MAPK) cascade is a major signaling system by which cells transduce extracellular cues into intracellular responses (Nishida er a/., Trends Biochem. Sci. 18:128 (1993); Blumer ef al., Trends Biochem. Sci. 19:236 (1994)). Many steps of this cascade are conserved, and homologous for MAP kinases have been discovered in different species.
• Extracellular-Signal-Regulated Kinases ERKs
• ERK-1 and ERK-2 are the archetypal and best-studied members of the MAPK family, which all have the unique feature of being activated by phosphorylation on threonine and tyrosine residues by an upstream dual specificity kinase (Posada et al., Science 255:212 (1992); Biggs III et al., Proc. Natl. Acad. Sci. USA 89:6295 (1992); Garner et al., Genes Dev. 6:1280 (1992)). Recent studies have identified an additional subgroup of
• JNK-1 and JNK-2 c-Jun NH2-terminal kinases 1 and 2
• JNK-2 c-Jun NH2-terminal kinases 1 and 2
• SPKs stress-activated protein kinases
• JNKs have been shown to be activated by treatment of cells with UV radiation, pro-inflammatory cytokines and environmental stress (Derijard era/., Cell 1025 (1994)).
• the activated JNK binds to the amino terminus of the c-Jun protein and increases the protein's transcriptional activity by phosphorylating it at ser63 and ser73 (Adler ef al., Proc. Natl. Acad. Sci. USA 89:5341 (1992); Kwok et al., Nature 370:223 (1994)).
• Thr-Pro-Tyr JNK
• Thr-Glu-Tyr ERK
• Phosphorylation of MAPKs and JNKs by an external signal often involves the activation of protein tyrosine kinases (PTKs) (Gille et al., Nature 358:414 (1992)), which constitute a large family of proteins encompassing several growth factor receptors and other signal transducing molecules.
• PTKs protein tyrosine kinases
• Protein tyrosine kinases are enzymes which catalyze a well defined chemical reaction: the phosphorylation of a tyrosine residue (Hunter et al., Annu Rev Biochem 54:897 (1985)). Receptor tyrosine kinases in particular are attractive targets for drug design since blockers for the substrate domain of these kinases is likely to yield an effective and selective antiproliferative agent.
• the potential use of protein tyrosine kinase blockers as antiproliferative agents was recognized as early as 1981 , when quercetin was suggested as a PTK blocker (Graziani et al., Eur. J. Biochem. 135:583-589 (1983)).
• MAPK extracellular signal-regulated kinases which constitute the Ras/Raf/MEK/ERK kinase cascade (Boudewijn et al., Trends Biochem. Sci. 20, 18 (1995)). Once this pathway is activated by different stimuli, MAPK phosphorylates a variety of proteins including several transcription factors which translocate into the nucleus and activate gene transcription. Negative regulation of this pathway could arrest the cascade of these events.
• Oncoproteins in general, and signal transducing proteins in particular, are likely to be more selective targets for chemotherapy because they represent a subclass of proteins whose activities are essential for cell proliferation, and because their activities are greatly amplified in proliferative diseases.
• the biologically active compounds are in the form of (E)-styryl benzylsulfones.
• the intermediates comprise (E)-styryl benzylsulfonyl acetic acids.
• novel compounds are provided according to formula I:
• R v R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen; fluoro; chloro; bromo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and trifluoromethyl;
• R 1 ; R 2 , R 3 , and R 4 may not all be hydrogen;
• R 4 when R R 2 , and R 3 are hydrogen, then R 4 may not be:
• R 4 when R., and R 3 are hydrogen and R 2 is 4-chloro, then R 4 may not be 4-chloro, 4-fluoro, 4-bromo, 4-nitro, 4-isopropyl or 4-ethoxy; (d) when R., and R 3 are hydrogen and R 2 is 4-fluoro, then R 4 may not be 4-fluoro, 4-bromo, or 4-chloro
• R 4 when R., and R 3 are hydrogen and R 2 is 4-nitro, then R 4 may not be 4-chloro, 4-nitro, 4-bromo, 4-fluoro, 4-methyl, or 4-methoxy; (f) when R and R 3 are hydrogen and R 2 is 4-methyl, R 4 may not be 4-chloro, 4-bromo, 4-fluoro, 4-methyl or 2-chloro;
• R 1 and R 3 are hydrogen and R 2 is 4-bromo, then R 2 may not be 4-fluoro, 4-bromo or 4-chloro;
• R 3 and R 4 may not be 2, 4-dichloro, 2,3-dimethoxy or 3,4-dimethoxy;
• R. when R., is hydrogen, then R 2 , R 3 and R 4 may not all be fluoro;
• R 2 and R 4 may not both be selected from the group consisting of 4-chloro, 4-bromo, and 4-fluoro.
• novel compounds are provided according to formula I wherein R.,, R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, chloro, fluoro, bromo, nitro, cyano and thfluoromethyl. According to a more preferred embodiment, R R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, chloro, fluoro and bromo; most preferably hydrogen, chloro and fluoro.
• novel compounds are provided according to formula I wherein (1 ) at least one of R ⁇ and R 2 is other than hydrogen and is located at the 2-, 3- and/or 4- position of the phenyl ring to which it is attached, and is preferably selected from chloro and fluoro, most preferably chloro; and/or (2) wherein at least one of R 3 and R 4 is other than hydrogen and is located at the 2- and/or 4- position of the phenyl ring to which it is attached, and is preferably selected from chloro and fluoro.
• R 1 and R 2 are other than hydrogen, and at least one of R 3 and R 4 is other than hydrogen
• R 2 is 4-halogen or 4-cyano, and R 4 is 4-nitro
• R., and R 3 are preferably hydrogen in these embodiments.
• composition comprising a pharmaceutically acceptable carrier and one or more compounds of formula II:
• R.,, R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen; fluoro; chloro; bromo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and thfluoromethyl;
• R 1f R 2 , and R 3 are not all hydrogen when R 4 is 2-chloro or 4-chloro;
• R 4 when R 1 and R 3 are hydrogen and R 2 is 4-bromo or 4- chloro, then R 4 may not be 4-chloro, 4-fluoro or 4-bromo;
• R., and R 3 are hydrogen and R 2 is 4-fluoro, R 4 may not be 4-fluoro or 4-bromo;
• R 1 when R 1 is hydrogen, and R 4 is 2-fluoro, then R 2 and R 3 may not be 4-fluoro; (e) when R 1 is hydrogen and R 3 is 4-hydrogen, 4-chloro, 4- bromo, 4-methyl or 4-methoxy, and R 4 is 2-hydrogen, 2-chloro or 2-fluoro; then R 2 may not be 4-hydrogen, 4-chloro, 4-fluoro or 4-bromo.
• R.,, R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen; fluoro; chloro; bromo; iodo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and thfluoromethyl; provided at least one of R.,, R 2 , R 3 , and R 4 is iodo.
• At least one of R 1 and R 2 in formula III is other than hydrogen and is located at the 2- or 4- position of the phenyl ring to which it is attached; and at least one of R 3 and R 4 is other than hydrogen and is located at the 2- or 4-position of the phenyl ring to which it is attached.
• R 2 and R 4 in formula III are hydrogen, and R., and R 3 are located at the 4-position of the respective phenyl rings to which they are attached.
• one of R 1 or R 3 is selected from the group consisting of chloro, fluoro, bromo and nitro, the other of R 1 or R 3 being iodo.
• a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of formula III above, wherein R.,, R 2 , R 3 , and R 4 are defined as above for formula III.
• R.,, R 2 , R 3 or R 4 is an alkyl or alkoxy group in any compound of formulae I, II or III, the carbon chain may be branched or straight, with straight being preferred.
• the alkyl and alkoxy groups comprise C1-C3 alkyl and C1-C4 alkoxy, most preferably methyl and methoxy.
• a method of treating an individual for a proliferative disorder, particularly cancer comprising administering to said individual an effective amount of a compound according to formula II or 111, alone or in combination with a pharmaceutically acceptable carrier.
• a method of inhibiting growth of tumor cells in an individual afflicted with cancer comprising administering to said individual an effective amount of a compound according to formula II or 111, alone or in combination with a pharmaceutically acceptable carrier.
• a method of inducing apoptosis of cancer cells, more preferably tumor cells, in an individual afflicted with cancer comprising administering to said individual an effective amount of a compound according to formula II or 111, alone or in combination with a pharmaceutically acceptable carrier.
• benzyl sulfones having the structural formula II or III may be utilized as monomers in the synthesis of a new class of polymers having pendant benzylsulfone groups.
• the present invention also provides a series of substituted benzylsulfonyl acetic acid compounds having structural formula V, below.
• the substituted benzylsulfonyl acetic acid compounds are useful as intermediates in the synthesis of novel (E)-styryl benzylsulfone compounds of formula I, according to Method A, below.
• certain (E)-styryl benzylsulfone derivatives selectively kill various tumor cell types without killing normal cells.
• the compounds affect the MAPK signal transduction pathway, thereby affecting tumor cell growth and viability. This cell growth inhibition is associated with regulation of the ERK and JNK types of MAPK.
• the styryl sulfones of the present invention may block the phosphorylating capacity of ERK-2.
• the compounds of the invention have been shown to inhibit the proliferation of tumor cells by inducing cell death.
• the compounds are believed effective against a broad range of tumor types, including but not limited to the following: breast, prostate, ovarian, lung, colorectal, brain (i.e, glioma) and renal.
• the compounds are also believed effective against leukemic cells.
• the compounds do not kill normal cells in concentrations at which tumor cells are killed.
• the compounds are also useful in the treatment of non- cancer proliferative disorders, including but not limited to the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganlioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
• non- cancer proliferative disorders including but not limited to the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganlioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
• styryl benzylsulfone compounds of the invention leads to inhibition of cell proliferation and induction of apoptotic cell death.
• the effect is observed for estrogen receptor (ER) positive as well as estrogen receptor negative cells.
• Tumor cells treated with the compounds of the invention accumulate in the G2/M phase of the cell cycle. As the cells exit the G2/M phase, they appear to undergo apoptosis. Treatment of normal cells with the styryl sulfones does not result in apoptosis.
• the styryl benzylsulfones are characterized by cis-trans isomehsm resulting from the presence of one or more double bonds.
• the compounds are named according to the Cahn-lngold-Prelog system, the IUPAC 1974 Recommendations, Section E: Stereochemistry, in Nomenclature of Organic Chemistry, John Wiley & Sons, Inc., New York, NY, 4 th ed., 1992, p. 127-138. Steahc relations around a double bond are designated as "Z" or "E".
• (E)-styryl benzylsulfones are prepared by Knoevenagel condensation of aromatic aldehydes with benzylsulfonyl acetic acids. The procedure is described by Reddy eta I., Ada. Chim. Hung. 115:269 (1984); Reddy et al., Sulfur Letters 13:83 (1991 ); Reddy et al., Synthesis 322 (1984); and Reddy et al., Sulfur Letters 7:43 (1987), the entire disclosures of which are incorporated herein by reference.
• the (E)-styryl benzylsulfones can be prepared according to either of the following Methods A and B:
• a benzyl thioacetic acid V formed by the reaction of sodium thioglycollate and a benzyl chlo ⁇ de IV.
• the benzyl thioacetic acid V is oxidized with 30% hydrogen peroxide to give a corresponding benzylsulfonyl acetic acid VI.
• Condensation of VI with an aromatic aldehyde VII via a Knoevenagel reaction in the presence of benzylamine and glacial acetic acid yields the (E)-styryl benzylsulfone I, II or III.
• a benzylthioacetic acid V is formed by the reaction of the appropriate sodium benzylthiolate VIII with chloroacetic acid.
• Substituted benzylsulfonyl acetic acid compounds Va, Vb, Vc, and Vd according to formula V were prepared by reacting the corresponding benzyl chloride with thioglycollic acid under basic conditions (Method A). These compounds are novel intermediates.
• (E)-Styryl benzylsulfones may be utilized as monomers in the synthesis of polymers X having pendant aryl and benzylsulfone groups.
• the polymerization of styryl benzylsulfones defined according to formula IX below into formula X polymers is accomplished by heating the formula IX compound above 250 °C in the presence of a free radical initiator.
• the initiator may comprise benzoyl peroxide, for example:
• the degree of polymerization in the polymer of formula X, "x" may range from about 10 to about 150, providing an oligomer or polymer of from 5,000 to 50,000 daltons. Other degrees of polymerization are also contemplated.
• R 1 ( R 2 , R 3 , and R 4 in the monomer of formula IX, and in the polymer of formula X, are independently selected from the group consisting of hydrogen; halogen, i.e., fluoro, chloro, bromo and iodo, most preferably fluoro, chloro and bromo; C1-C6 alkyl; C1-C6 alkoxy; nitro; cyano; and thfluoromethyl.
• the (E)-styryl benzylsulfones may be derivatized with a chemical group to permit conjugation to a carrier molecule, for the purpose of raising antibodies to the styryl sulfones. Suitable derivatizing chemistries are well-known to those skilled in the art.
• the derivative comprises a carboxylic acid derivative.
• the carrier may comprise any molecule sufficiently large to be capable of generating an immune response in an appropriate host animal.
• One such preferred carrier is keyhole limpet haemocyanin (KLH).
• the (E)-styryl benzylsulfones of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier.
• the active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent.
• pharmaceutically acceptable carrier is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and to deleterious to the recipient.
• the compounds of the invention may be administered to individuals (mammals, including animals and humans) afflicted with cancer. The compounds are also useful in the treatment of non-cancer proliferative disorders, that is, proliferative disorders which are characterized by benign indications.
• Such disorders may also be known as "cytoproliferative” or “hyperproliferative” in that cells are made by the body at an atypically elevated rate.
• Such disorders include, but are not limited to, the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
• the compounds may be administered by any route, including oral and parenteral administration.
• Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravaginal, topical or subcutaneous administration.
• the active agent is preferably administered with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice.
• the active agent may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations. See Gennaro Alphonso, ed., Remington's Pharmaceutical Sciences, 18th Ed., (1990) Mack Publishing Co., Easton, PA. Suitable dosage forms may comprise, for example, tablets, capsules, solutions, parenteral solutions, troches, suppositories, or suspensions.
• the active agent may be mixed with a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol.
• Solutions for parenteral administration preferably contain a water soluble salt of the active agent. Stabilizing agents, antioxidizing agents and preservatives may also be added. Suitable antioxidizing agents include sulfite, ascorbic acid, citric acid and its salts, and sodium EDTA. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorbutanol.
• the composition for parenteral administration may take the form of an aqueous or nonaqueous solution, dispersion, suspension or emulsion.
• the active agent may be combined with one or more solid inactive ingredients for the preparation of tablets, capsules, pills, powders, granules or other suitable oral dosage forms.
• the active agent may be combined with at least one excipient such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents absorbents or lubricating agents.
• the active agent may be combined with carboxymethylcellulose calcium, magnesium stearate, mannitol and starch, and then formed into tablets by conventional tableting methods.
• the specific dose of compound according to the invention to obtain therapeutic benefit will, of course, be determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient, the nature and stage of the disease, the aggressiveness of the disease, and the route of administration.
• a daily dosage of from about 0.05 to about 50 mg/kg/day may be utilized. Higher or lower doses are also contemplated.
• the substituted benzylsulfonyl acetic acid was made according to Part A of the General Procedure. All the styryl benzylsulfone compounds were recrystalized from 2-propanol and the purity was checked by thin layer chromatography.
• breast tumor cell lines MCF-7 and BT-20 breast tumor cell lines MCF-7 and BT-20; prostate tumor cell line DU-145; colorectal carcinoma cell line DLD-1 ; non- small cell lung carcinoma cell line H157; and NIH/3T3 and HFL cells.
• MCF- 7 is estrogen-responsive
• BT-20 is an estrogen-unresponsive cell line.
• NIH/3T3 and HFL are normal murine and human fibroblasts, respectively.
• MCF-7, BT-20, DLD-1 and H157 were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum supplemented with penicillin and streptomycin.
• DU145 was cultured in RPMI with 10% fetal bovine serum containing penicillin and streptomycin.
• NIH3T3 and HFL cells were grown in DMEM containing 10% calf serum supplemented with penicillin and streptomycin. All cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
• Normal cells HFL and NIH 3T3 were treated with the same compounds in Table 2 under the same conditions of concentration and time. The normal cells displayed 5% growth inhibition but no appreciable cell death.
• Example 68 Conjugation of (E)-4-Fluorostyryl 4-chlorobenzylsulfone to Keyhole Limpet Haemocyanin
• a carboxylic acid derivative of (E)-4-fluorostyryl 4- chlorobenzylsulfone was synthesized by mixing 4-chlorobenzyl sulfonyl acetic acid (10 mmol), 4-fluorobenzaldehyde (10mmol), glacial acetic acid (15 ml) and piperidine (0.5 ml) at room temperature (22°C) over a magnetic stirrerfor ⁇ hours. The mixture was then diluted with ether and the ethereal layer was washed with water. Evaporation of the ethereal layer yielded a semisolid material which on treating with 2-propanol gave a white solid.
• the above carboxylic acid derivative (10 mM) was made into an active ester by treatment with 10 mM 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 10 mM N- hydroxysuccinamide (NHS), and then cross-linked to KLH by mixing with 1 ml of a KLH water solution containing 500 mg KLH. The mixture was stirred at room temperature for 5-6 hours. The KLH conjugate was then separated by passing the mixture through a size exclusion column (PD 10, Pharmacia). The conjugate was then used to inject rabbits for raising antibodies.
• EDC 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride
• NHS N- hydroxysuccinamide

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Physical Education & Sports Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Rheumatology (AREA)
• Neurosurgery (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Pulmonology (AREA)
• Gastroenterology & Hepatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=26825868

Family Applications (1)

Country Status (7)

Cited By (5)

Families Citing this family (6)

Citations (1)

Family Cites Families (6)

• 2000
  • 2000-03-31 WO PCT/US2000/008565 patent/WO2000059495A1/en not_active Ceased
  • 2000-03-31 AT AT00921553T patent/ATE298234T1/de active
  • 2000-03-31 DE DE60020954T patent/DE60020954T2/de not_active Expired - Lifetime
  • 2000-03-31 JP JP2000609059A patent/JP4596651B2/ja not_active Expired - Fee Related
  • 2000-03-31 AU AU41853/00A patent/AU774738B2/en not_active Ceased
  • 2000-03-31 EP EP00921553A patent/EP1173160B1/en not_active Expired - Lifetime
  • 2000-03-31 CA CA2366750A patent/CA2366750C/en not_active Expired - Fee Related

Patent Citations (1)

Non-Patent Citations (14)

Also Published As

Similar Documents

Legal Events